TORONTO, July 29, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of Alberta, for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Alberta Health is effective August 1, 2024.
Read more at newswire.caHLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.